biosimilars

The Amgen headquarters in Thousand Oaks, Calif. (AP/Mark J. Terrill)
The Supreme Court dealt a blow to big pharma on Monday, ruling that companies making generic “biosimilars” to brand-name drugs don’t have to wait an extra six months after gaining federal approval before selling their drugs.
The ruling, written by Justice Clarence Thomas for the unanimous court, is expected to speed up how quickly generic drugs become available to consumers.